Finerenone in Patients with Focal Segmental Glomerulosclerosis
Background: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). Methods: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m 2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Results: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m 2 , and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m 2 /year (95% CI, 0.5–2.2; P =0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m 2 /year), and among participants with primary or secondary FSGS ( P -interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30–1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%–53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0–17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Conclusions: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.
Authors
- Susanne B. Nicholas (ORCID: https://orcid.org/0000-0003-3535-9120)
- Jürgen Floege
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Mario Berger (ORCID: https://orcid.org/0000-0002-9048-3928)
- Niels Jongs (ORCID: https://orcid.org/0000-0002-0882-3656)
- Marijn M. Speeckaert (ORCID: https://orcid.org/0000-0001-9183-4390)
- Pantelis A. Sarafidis (ORCID: https://orcid.org/0000-0002-9174-4018)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- Alfredo Chew‐Wong
- Glenn Matthew Chertow (ORCID: https://orcid.org/0000-0002-7599-0534)
- Pablo E. Pérgola (ORCID: https://orcid.org/0000-0002-5876-894X)
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Patrick Schloemer (ORCID: https://orcid.org/0009-0004-7787-5662)
- MEIKE DANIELA BRINKER (ORCID: https://orcid.org/0000-0002-1560-9535)
- Jonathan Barratt (ORCID: https://orcid.org/0000-0002-9063-7229)
- Hirokazu Okada (ORCID: https://orcid.org/0000-0002-1839-9078)
- Tim Friede (ORCID: https://orcid.org/0000-0001-5347-7441)
- Vladimir Dobronravov (ORCID: https://orcid.org/0000-0002-7179-5520)
- Rania Dayoub (ORCID: https://orcid.org/0000-0001-5848-5571)
- Johannes David Smeijer (ORCID: https://orcid.org/0000-0003-1725-9927)
- Aidan MacNamara (ORCID: https://orcid.org/0000-0001-5958-2429)
- Carolina Aldworth (ORCID: https://orcid.org/0009-0009-8334-4311)
- Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
- David Packham
- Rajiv Agarwal (ORCID: https://orcid.org/0000-0001-8355-7100)
- 汤水福
- Vlado Perkovic
- Marina Yael Finkelsztein
- for the FIND-CKD Investigators
Institutions
- Guangzhou University of Chinese Medicine (CN)
- The Royal Melbourne Hospital (AU)
- University Health Network (CA)
- University Medical Center Groningen (NL)
- Bayer (United States) (US)
- University of Leicester (GB)
- University of California, Los Angeles (US)
- National University of Singapore (SG)
- University of Groningen (NL)
- University of Toronto (CA)
- University of Washington (US)
- Aristotle University of Thessaloniki (GR)
- University of Würzburg (DE)
- First Pavlov State Medical University of St. Petersburg (RU)
- Royal North Shore Hospital (AU)
- Leicester General Hospital (GB)
- Toronto General Hospital (CA)
- University Hospital Regensburg (DE)
- UNSW Sydney (AU)
- Ghent University (BE)
- Richard L. Roudebush VA Medical Center (US)
- The George Institute for Global Health (AU)
- Ippokrateio General Hospital of Thessaloniki (GR)
- Universitätsmedizin Göttingen (DE)
- Universitätsklinikum Aachen (DE)
- Duke-NUS Medical School (SG)
- Stanford Medicine (US)
- National Heart Centre Singapore (SG)
- Renal Associates P. A. (US)
- Indiana University School of Medicine (US)
- Bayer (Germany) (DE)
- Saitama Medical University (JP)
- Stanford University (US)
Publication Details
- Journal
- Journal of the American Society of Nephrology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1681/asn.0000001333
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00